26 January 2025 : Clinical Research
Impact of Periodontal Treatment on Early Rheumatoid Arthritis and the Role of Porphyromonas gingivalis Antibody Titers
Yoichiro Nakajima
1ABCDEF, Nahoko Kato-Kogoe 1ABCDEF*, Takako Yasuda2ABC, Rika Urakawa2BC, Tomoka Matsuo1DF, Michi Omori1BDF, Takaaki Ueno1ADEF, Tohru Takeuchi3ADE
DOI: 10.12659/MSM.947146
Med Sci Monit 2025; 31:e947146
Table 1 Baseline characteristics of the patients in each group with different timing of periodontal treatment initiation.
| Variables | Group A (n=9) | Group B (n=10) | Group C (n=11) | P value | P value A vs B | P value A vs C |
|---|---|---|---|---|---|---|
| Age (years) | 68 (55–71) | 71 (67–74) | 68 (47–70) | 0.414 | 0.356 | 0.656 |
| Sex (Female %) | 88.9% | 60.0% | 54.5% | 0.231 | 0.153 | 0.095 |
| Number of teeth | 24 (20–27) | 20 (16–27) | 25 (20–28) | 0.223 | 0.447 | 0.370 |
| Number of teeth with periodontal pocket depth 4–6 mm | 8 (7–12) | 5 (3–8) | 9 (3–10) | 0.326 | 0.113 | 0.603 |
| Number of teeth with periodontal pocket depth ≥6 mm | 0 (0–2) | 0 (0–1) | 0 (0–0) | 0.532 | 0.720 | 0.412 |
| Number of teeth with bleeding on probing | 0 (0–4) | 1 (0–3) | 1 (0–4) | 0.947 | 0.720 | 0.941 |
| PISA | 0.0 (0.0–343.2) | 13.2 (0.0–225.1) | 28.7 (0.0–190.1) | 0.993 | 0.905 | 0.882 |
| Periodontitis (no/mild/moderate/severe, n)# | 0/3/4/2 | 0/5/3/2 | 0/5/4/2 | 0.826 | 0.604 | 0.656 |
| Serum antibody titers (log.) | 3.13 (2.74–3.34) | 2.80 (0.00–3.09) | 2.60 (0.00–3.27) | 0.356 | 0.182 | 0.295 |
| (Baseline/0–12M, n) | ||||||
| bDMARDs use | 0/1 | 0/2 | 0/3 | −/0.668 | −/0.596 | −/0.369 |
| csDMARDs use | 0/9 | 0/10 | 11/11 | 0.000/− | −/− | 0.000/− |
| Steroid use | 0/0 | 0/1 | 3/3 | 0.056/0.189 | −/0.330 | 0.089/0.089 |
| Results are expressed as the median (interquartile range) or n (number). The values are the results of comparisons using Kruskal-Wallis test, Mann-Whitney U test, or chi-square test. PISA – periodontal inflammatory surface area; bDMARDs – biological disease-modifying antirheumatic drugs; csDMARDs – conventional synthetic disease-modifying antirheumatic drugs. # The presence and severity of periodontitis were determined according to the Centers for Disease Control and Prevention in collaboration with the American Academy of Periodontology (CDC/AAP) case definition []. | ||||||